J. S. Elborn, Cystic fibrosis. The Lancet, vol.388, pp.2519-2550, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02299268

C. E. Wainwright, J. S. Elborn, B. W. Ramsey, G. Marigowda, X. Huang et al.,

, Patients with Cystic Fibrosis Homozygous for Phe508del CFTR, vol.373, pp.220-251, 2015.

J. S. Elborn, B. W. Ramsey, M. P. Boyle, M. W. Konstan, X. Huang et al., Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. The Lancet Respiratory Medicine, vol.4, pp.617-643, 2016.

A. M. Jones and P. J. Barry, Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax, vol.70, pp.615-621, 2015.

J. S. Elborn, B. Ramsey, C. Wainwright, and M. Boyle, Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm, Thorax, vol.71, issue.2, pp.185-191, 2016.

A. Masson, E. K. Schneider-futschik, N. Baatallah, T. Nguyen-khoa, E. Girodon et al., Predictive factors for lumacaftor/ivacaftor clinical response, Journal of Cystic Fibrosis, vol.18, issue.3, pp.368-74, 2019.

P. Burgel, A. Munck, I. Durieu, R. Chiron, L. Mely et al., Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02451455

A. D. Calder, A. Bush, A. S. Brody, and C. M. Owens, Scoring of chest CT in children with cystic fibrosis: state of the art, Pediatric Radiology, vol.44, issue.12, pp.1496-506, 2014.

M. Loeve, P. Van-hal, P. Robinson, P. A. De-jong, M. H. Lequin et al., The spectrum of structural abnormalities on CT scans from patients with CF with severe advanced lung disease, Thorax, vol.64, issue.10, pp.876-82, 2009.

A. S. Brody, J. S. Klein, P. L. Molina, J. Quan, J. A. Bean et al., High-resolution computed tomography in young patients with cystic fibrosis: Distribution of abnormalities and correlation with pulmonary function tests, The Journal of Pediatrics, vol.145, issue.1, pp.32-40, 2004.

G. Chassagnon, D. Hubert, I. Fajac, P. Burgel, and M. Revel, Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor, European Respiratory Journal, vol.48, issue.1, pp.249-52, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01416766

S. I. Sheikh, F. R. Long, K. S. Mccoy, T. Johnson, N. A. Ryan-wenger et al., Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation, Journal of Cystic Fibrosis, vol.14, issue.1, pp.84-93, 2015.

F. Ratjen, C. Hug, G. Marigowda, S. Tian, X. Huang et al., Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine, vol.5, pp.557-67, 2017.

J. J. Mcnamara, S. A. Mccolley, G. Marigowda, F. Liu, S. Tian et al., Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine, vol.7, pp.325-360, 2019.

J. L. Taylor-cousar, A. Munck, E. F. Mckone, C. K. Van-der-ent, A. Moeller et al.,

, Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del, N Engl J Med, vol.377, issue.21, pp.2013-2036, 2017.

D. Keating, G. Marigowda, L. Burr, C. Daines, M. A. Mall et al., , p.445

, Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N Engl J Med, vol.379, issue.17, pp.1612-1632, 2018.

J. C. Davies, S. M. Moskowitz, C. Brown, A. Horsley, M. A. Mall et al., VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles, N Engl J Med, vol.379, issue.17, pp.1599-611, 2018.

F. Holguin, Triple CFTR Modulator Therapy for Cystic Fibrosis, N Engl J Med, vol.379, issue.17, pp.1671-1673, 2018.